Treatment for Interstitial Pneumonia
Treatment depends critically on the specific type of interstitial pneumonia: antifibrotic therapy (pirfenidone or nintedanib) is indicated for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), while immunosuppressive therapy with corticosteroids ± immunosuppressants is the cornerstone for inflammatory patterns and autoimmune-related disease. 1
Diagnostic Classification Determines Treatment Strategy
The first step is determining whether you are dealing with:
- IPF with definite UIP pattern: Antifibrotic therapy is indicated 1
- Progressive pulmonary fibrosis (PPF): Antifibrotic therapy should be considered 1, 2
- Autoimmune-related interstitial pneumonia: Immunosuppressive therapy is preferred 3, 4
- Inflammatory-predominant NSIP: Corticosteroids ± immunosuppressants 5, 2
- Fibrotic-predominant NSIP: More complex; may require antifibrotics if progressive 5, 2
Antifibrotic Therapy
For IPF and PPF, antifibrotic drugs prevent approximately 50% of disease progression as measured by forced vital capacity decline 6:
- Pirfenidone or nintedanib are the two approved agents 6
- These have demonstrated robust treatment effects in preventing disease progression 6
- Antifibrotic treatment is specifically indicated for patients diagnosed with IPF 1
- Consider antifibrotics for other ILD types manifesting PPF 1, 2
Immunosuppressive Therapy
For autoimmune-related and inflammatory interstitial pneumonias, immunosuppression remains the primary approach:
Rheumatoid Arthritis-UIP and IPAF-UIP
- Immunosuppressive treatment produced promising results in these populations 3
- In IPAF-UIP patients, immunosuppressive therapy was superior to antifibrotic treatment for one-year FVC response (16/29 improved vs 4/27 improved, p=0.006) 4
- Quality of life (SGRQ) also improved significantly more with immunosuppression (p<0.001) 4
- In patients with histological inflammatory cell infiltration, survival was significantly better with immunosuppressive therapy (p=0.02) 4
Dermatomyositis/Polymyositis-Associated IP
- Primary intensive approach (starting immunosuppressants simultaneously with corticosteroids) was associated with significantly better survival compared to step-up approach (p=0.030) 7
- Waiting to add immunosuppressants only after corticosteroid failure resulted in worse outcomes 7
- This emphasizes the critical importance of aggressive initial treatment in active autoimmune-related IP 7
NSIP Patterns
Inflammatory-type NSIP (prominent lymphocytic inflammation on BAL, mixed NSIP/organizing pneumonia pattern on HRCT):
- Tends to have better response to corticosteroids and immunosuppressive treatment 5
- This represents the most treatment-responsive subgroup 5
Fibrotic-type NSIP (prominent reticular changes, traction bronchiectasis, high fibrotic background):
- Less potential to respond to immunosuppressive treatment 5
- May require antifibrotic therapy if progressive and refractory to immunosuppression 5, 2
- Treatment with systemic steroids alone or combined with immunosuppressants, though evidence is limited 2
Critical Caveats
Systemic sclerosis-UIP represents an important exception: UIP patients showed a non-significant trend toward worsening under immunosuppression 3. This highlights that different autoimmune diseases respond differently to immunosuppression.
Avoid immunosuppression in definite IPF: Following the PANTHER study results, immunosuppressive drugs are not recommended for IPF treatment 3, 6.
Probable UIP cases (possible UIP on HRCT without surgical biopsy) require multidisciplinary discussion to establish a working diagnosis before treatment decisions 6.
Supportive Care
Regardless of specific treatment:
- Oxygen therapy for hypoxemia 5
- Pulmonary rehabilitation 5
- Lung transplantation evaluation for severe, progressive, refractory disease 5